Aquestive Therapeutics, Inc. (AQST)

Name: Aquestive Therapeutics, Inc. (AQST) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001398733 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Aquestive Therapeutics, Inc. reported revenue of $44.55M. Revenue fell 22.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $54.09M.

Key ratios (year ended 2025-12-31)

58.3%

Gross margin (computed)

-159.5%

Operating margin

-188.1%

Net margin

-22.6%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Revenue	$54.09M	$44.55M	$57.56M	$50.58M	$47.68M	$50.83M	$45.85M	$52.61M	$67.43M	$66.92M
Cost of Revenue	$17.83M	$18.55M	$17.87M	$20.83M	$19.39M	n/a	$12.96M	$20.36M	n/a	n/a
Gross Profit (computed)	$36.26M	$25.99M	$39.69M	$29.75M	$28.29M	n/a	$32.88M	$32.25M	n/a	n/a
R&D Expense	$15.89M	$17.19M	$20.28M	$13.10M	$17.48M	$17.05M	$19.89M	$20.57M	$23.11M	$22.13M
Operating Income	-$52.74M	-$71.05M	-$30.77M	-$15.10M	-$42.07M	-$34.68M	-$42.89M	-$52.67M	-$48.93M	-$113.0K
Depreciation & Amortization	$518.0K	$548.0K	$718.0K	$1.34M	$2.39M	$2.96M	$3.44M	$2.90M	$3.24M	n/a
EBITDA	-$52.23M	-$70.50M	-$30.05M	-$13.76M	-$39.68M	-$31.71M	-$39.45M	-$49.76M	-$45.70M	n/a
Net Income	-$78.23M	-$83.78M	-$44.14M	-$7.87M	-$54.41M	-$70.54M	-$55.78M	-$66.25M	-$61.38M	-$8.94M
EPS (Diluted)	n/a	-$0.78	-$0.51	-$0.13	-$1.12	-$1.85	-$1.66	n/a	n/a	n/a
Total Assets	$132.10M	$160.43M	$101.42M	$57.42M	$57.07M	$61.99M	$62.88M	$78.48M	$86.85M	$43.12M
Total Liabilities	$188.69M	$194.09M	$161.58M	$163.91M	$175.62M	$144.13M	$111.38M	$84.60M	$76.77M	$69.61M
Long-Term Debt	$55.00M	$45.00M	$45.00M	$45.00M	n/a	n/a	$51.50M	$70.00M	n/a	n/a
Shareholders' Equity	-$56.59M	-$33.66M	-$60.16M	-$106.49M	-$118.55M	-$82.13M	-$48.50M	-$6.12M	$10.08M	-$68.60M
Cash & Equivalents	$98.49M	n/a	n/a	n/a	n/a	n/a	$31.81M	$49.33M	$60.60M	$17.38M
Operating Cash Flow	-$45.37M	-$52.43M	-$35.76M	-$6.38M	-$9.82M	-$32.98M	-$45.46M	-$60.21M	-$12.99M	$5.82M
Capital Expenditures	$584.0K	$562.0K	$159.0K	$995.0K	$1.02M	$913.0K	$517.0K	$663.0K	$1.82M	$2.07M
Free Cash Flow	-$45.95M	-$52.99M	-$35.92M	-$7.38M	-$10.84M	-$33.89M	-$45.98M	-$60.87M	-$14.81M	$3.76M
Shares Outstanding	125.51M	122.04M	91.41M	68.53M	54.83M	41.23M	34.57M	33.56M	24.96M	n/a
Weighted Average Diluted Shares	n/a	106.93M	86.73M	61.26M	48.73M	38.08M	33.65M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.78	-$0.51	-$0.13	-$1.12	-$1.85	-$1.66	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView